MEDICUS Pharma COO Buys 200,000 Zero‑Cost Options as SkinJect® Phase‑2b Launch Fuels Investor Optimism
MEDICUS Pharma’s COO buys 200 k zero‑cost options, signaling confidence ahead of SkinJect’s Phase‑2b study and orphan‑drug push—potential upside for investors.
3 minutes to read